Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥4,385.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥36.26B
Enterprise Value¥28.86B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)35.8
Beta1.16
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)25.93
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-94.5
Revenue Forecast (FY)¥451.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity base provide durable financial flexibility, lowering refinancing and solvency risk during long clinical development cycles. This supports sustained R&D investment, partnership negotiation power, and resilience to setbacks common in biotech development.
Operating Turnaround And Cash GenerationA shift to positive operating and free cash flow signals a structural improvement in cash generation capacity, reducing reliance on external capital. Sustained cash flow enables self-funding of late-stage trials, milestone-driven partnerships, and steadier capital allocation without recurring dilution.
Focused Regenerative Medicine PlatformA proprietary stem-cell platform addressing severe heart failure targets a large, underserved market with high clinical need. Platform-based IP and differentiated therapeutic approach increase long-term partnership, licensing and commercial potential, creating durable competitive moats if clinical success continues.
Bears Say
Prior Multi-year Losses And Cash BurnA history of multi-year losses and negative cash flow highlights execution and funding risk. Even with FY2025 recovery, prior burn indicates vulnerability to trial setbacks, cyclical funding, and potential future capital raises that can dilute shareholders and interrupt long-term planning.
Inconsistent Gross Profit ReportingInconsistent gross profit disclosure and anomalies reduce confidence in unit economics and margin sustainability. This opacity complicates forecasting of long-term profitability, pricing power, and scalability of the therapy platform across geographies and indications.
Dependence On External Funding And PartnershipsHeavy reliance on partnerships, grants and external capital exposes operations to funding cycle volatility and partner negotiation leverage. Long-term program continuity and commercialization pacing can be constrained by external funding availability and milestone outcomes.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥36.26B.
When is Heartseed, Inc.’s upcoming earnings report date?
Heartseed, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 90 days.
How were Heartseed, Inc.’s earnings last quarter?
Heartseed, Inc. released its earnings results on Jun 11, 2026. The company reported -¥2.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.54.
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,874,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Heartseed, Inc. reported an EPS of -¥2.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.149%.
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Headquartered in Tokyo, Japan, Heartseed, Inc. was established on November 30, 2015, by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa, and Yutaro Kasai. The company specializes in the development and advancement of cardiac regenerative medicine.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―